The TEVA PHARM ADR (TEVA) Downgraded by JPMorgan Chase & Co.

The TEVA PHARM ADR (TEVA) Downgraded by JPMorgan Chase & Co.

TEVA PHARM ADR (NYSE:TEVA) was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a note issued to investors on Friday.

A number of other equities research analysts have also recently commented on the stock. Cowen and Company restated a “buy” rating and set a $50.00 target price (down previously from $100.00) on shares of TEVA PHARM ADR in a research note on Tuesday, January 10th. RBC Capital Markets set a $42.00 target price on shares of TEVA PHARM ADR and gave the stock a “buy” rating in a research note on Monday, January 9th. Jefferies Group reiterated a “hold” rating and set a $36.00 price objective on shares of TEVA PHARM ADR in a research report on Monday, January 9th. Gabelli reiterated a “buy” rating on shares of TEVA PHARM ADR in a research report on Monday, January 9th. Finally, Wells Fargo & Co. cut shares of TEVA PHARM ADR from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $52.00 to $38.00 in a research report on Monday, January 9th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. TEVA PHARM ADR presently has a consensus rating of “Buy” and a consensus price target of $56.38.

Shares of TEVA PHARM ADR (NYSE:TEVA) opened at 33.47 on Friday. The stock has a 50 day moving average of $36.11 and a 200-day moving average of $45.20. The stock has a market cap of $33.97 billion, a PE ratio of 19.47 and a beta of 0.65. TEVA PHARM ADR has a 52 week low of $33.46 and a 52 week high of $64.31.

TEVA PHARM ADR (NYSE:TEVA) last released its earnings results on Tuesday, November 15th. The company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.02. TEVA PHARM ADR had a net margin of 8.81% and a return on equity of 16.75%. The company had revenue of $5.56 billion for the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter last year, the business earned $1.35 EPS. The firm’s revenue was up 15.3% compared to the same quarter last year. Equities research analysts predict that TEVA PHARM ADR will post $5.12 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the stock. Sharkey Howes & Javer increased its position in TEVA PHARM ADR by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock valued at $101,000 after buying an additional 358 shares during the period. Hudock Capital Group LLC increased its position in TEVA PHARM ADR by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock valued at $103,000 after buying an additional 564 shares during the period. Washington Trust Bank increased its position in TEVA PHARM ADR by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock valued at $103,000 after buying an additional 58 shares during the period. WFG Advisors LP increased its position in TEVA PHARM ADR by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock valued at $104,000 after buying an additional 256 shares during the period. Finally, Kistler Tiffany Companies LLC increased its position in TEVA PHARM ADR by 14.1% in the third quarter. Kistler Tiffany Companies LLC now owns 2,437 shares of the company’s stock valued at $112,000 after buying an additional 302 shares during the period. Hedge funds and other institutional investors own 54.53% of the company’s stock.

About TEVA PHARM ADR

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

Related posts

Leave a Comment